Biokin Pharma and Cryoport announced Cryoport’s full suite of temperature-controlled solutions will support Biokin Pharma’s pending Phase I and II clinical trials in immuno-oncology in both the U.S. and China. 

Biokin Pharma, is a biopharmaceutical company based in China focused on the treatment of cancer through developing novel therapeutic antibodies and antibody-drug conjugates. Its wholly-owned subsidiary SystImmune, which is funded in part by OrbiMed, was formed to advance its mission in the United States. 

Partnering with Cryoport will enable Biokin Pharma and SystImmune to utilize Cryoport’s full range of temperature-controlled logistics solutions to support its drug manufacturing processes across the globe. These solutions include the Cryoport Express® shippers, the industry-leading Cryoportal Logistics Management Platform, Smartpak II Condition Monitoring System and 24/7/365 logistics support.

“We are pleased to choose the highly reliable condition- and time-sensitive logistics solutions provided by Cryoport to support our upcoming clinical studies using Bispecific and Multi-specific Antibody, ADC, and T-cell Therapy,” said Dr. Yi Zhu, chairman of Biokin Pharma and its U.S. subsidiary, Systimmune of Seattle, WA. “By relying on Cryoport’s excellent solutions, Biokin Pharma and Systimmune will continue to have the best possible viability and recovery of critical cells, vectors, antibodies and other materials, even after time-consuming international or domestic transportation, to ensure the best outcome for our patients.”

“As the regenerative medicine market rapidly matures, the demand for our technology-driven solutions to support trials across the globe is growing. We look forward to working alongside Biokin Pharma and its U.S. subsidiary to ensure reliable, secure logistics support for their temperature-sensitive commodities as they advance the development of potentially life-saving therapies,” said Mark Sawicki, PhD, chief commercial officer of Cryoport.